Trial Profile
A retrospective study of ponatinib in treatment of advanced gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor (TKI) failure
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Jun 2017
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2017 New trial record